Gary J. Kelloff; Ernest T. Hawk; Caroline C. Sigma Cancer Chemoprevention 9781627038171

Варианты приобретения

Цена: 39130.00р.
Кол-во:
Наличие: Поставка под заказ. Есть в наличии на складе поставщика.
Склад Америка: Есть
При оформлении заказа до: 2025-07-28
Ориентировочная дата поставки: Август-начало Сентября
При условии наличия книги у поставщика.

Добавить в корзину

в Мои желания

Автор: Gary J. Kelloff; Ernest T. Hawk; Caroline C. Sigma
Название: Cancer Chemoprevention
ISBN: 9781627038171
Издательство: Springer
Классификация:

Онкология

ISBN-10: 1627038175
Обложка/Формат: Paperback
Страницы: 576
Вес: 1.40 кг.
Дата издания: 2005
Серия: Cancer Drug Discovery and Development
Язык: English
Издание: 2005 ed.
Иллюстрации: Xxi, 543 p.
Размер: 279 x 210 x 30
Читательская аудитория: Professional & vocational
Подзаголовок: Volume 2: strategies for cancer chemoprevention
Ссылка на Издательство: Link
Рейтинг:
Поставляется из: Германии
Описание: Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development—those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can “reasonably predict” clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.
Дополнительное описание: Chemopreventive Agent Development Science.- Characterization of Natural Product Chemopreventive Agents.- Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs.- Potential Use of Transgenic Mice in Chemoprevention Studies.- Modeling

Cancer Chemoprevention, Gary J. Kelloff; Ernest T. Hawk; Caroline C. Sigma